External oblique intercostal block with or without intravenous lidocaine infusion for analgesia in patients undergoing gastric bypass surgery: a randomized controlled trial
NCT ID NCT07809425
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
Adding a perioperative lidocaine infusion (1.5 mg/kg loading + 1.5 mg/kg/h) to bilateral EOIB and low dose fentanyl loading reduces intraoperative fentanyl consumption (ANI guided rescue) compared to placebo, without increasing adverse events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-60 years. * BMI ≥ 35 kg/m². * ASA physical status II or III. * Scheduled for elective laparoscopic Roux en Y gastric bypass. * Ability to provide written informed consent. Exclusion Criteria: * Refusal. * Allergy or contraindication to lidocaine, fentanyl, ropivacaine, or any study medication. * Chronic opioid use or dependence. * Significant hepatic (AST/ALT\> 3× normal, cirrhosis) or renal impairment (CrCl\< 30 mL/min). * Second or third degree AV block or significant bradyarrhythmia without pacemaker. * Coagulopathy, anticoagulation incompatible with regional anesthesia, or infection at block site. * Pregnancy or lactation. * Severe psychiatric or cognitive disorder. * Failed bilateral EOIB (absence of sensory loss in T6-T10 after 30 min) - excluded from analysis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obese patients are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Faculty of Medicine
RECRUITINGAlexandria, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill KDS2010 aims to shed pounds in obesity trial
- Obesity blocks kidney transplants: new study investigates why
- Exercise as medicine: 10-week program targets diabetes and high blood pressure in seniors
- Virtual wellness program aims to make healthy habits last
- Could a High-Fat diet help brain tumor patients lose weight?
- Gut bacteria secrets after Weight-Loss surgery revealed in new study